AUROPHARMAPharmaceuticals
Aurobindo Pharma Ltd — Profit & Loss Statement
₹1304.40
+0.49%
Aurobindo Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | -53.05 Cr | -2.81 Cr | -12.97 Cr | — |
| Tax Rate For Calcs | 0.31 | 0.28 | 0.26 | 0.11 | — |
| Normalized EBITDA | 7.17K Cr | 6.38K Cr | 4.00K Cr | 4.65K Cr | — |
| Total Unusual Items | 0.00 | -191.86 Cr | -10.73 Cr | -116.21 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | -191.86 Cr | -10.73 Cr | -116.21 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 3.49K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Reconciled Depreciation | 1.65K Cr | 1.52K Cr | 1.24K Cr | 1.13K Cr | — |
| Reconciled Cost Of Revenue | 13.03K Cr | 12.60K Cr | 11.90K Cr | 10.82K Cr | — |
| EBITDA | 7.17K Cr | 6.19K Cr | 3.99K Cr | 4.54K Cr | — |
| EBIT | 5.52K Cr | 4.67K Cr | 2.74K Cr | 3.41K Cr | — |
| Net Interest Income | -457.24 Cr | -289.71 Cr | 5.41 Cr | -17.04 Cr | — |
| Interest Expense | 457.24 Cr | 289.71 Cr | 128.95 Cr | 36.84 Cr | — |
| Normalized Income | 3.49K Cr | 3.31K Cr | 1.94K Cr | 2.75K Cr | — |
| Net Income From Continuing And Discontinued Operation | 3.49K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Total Expenses | 26.42K Cr | 24.38K Cr | 22.08K Cr | 20.07K Cr | — |
| Diluted Average Shares | 58.28 Cr | 58.59 Cr | 58.59 Cr | 58.59 Cr | — |
| Basic Average Shares | 58.28 Cr | 58.59 Cr | 58.59 Cr | 58.59 Cr | — |
| Diluted EPS | 59.81 | 54.16 | 32.90 | 45.19 | — |
| Basic EPS | 59.81 | 54.16 | 32.90 | 45.19 | — |
| Diluted NI Availto Com Stockholders | 3.49K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Net Income Common Stockholders | 3.49K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 3.49K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Minority Interests | 2.32 Cr | 4.00 Cr | -0.15 Cr | 1.04 Cr | — |
| Net Income Including Noncontrolling Interests | 3.48K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Net Income Continuous Operations | 3.48K Cr | 3.17K Cr | 1.93K Cr | 2.65K Cr | — |
| Tax Provision | 1.58K Cr | 1.21K Cr | 684.85 Cr | 725.63 Cr | — |
| Pretax Income | 5.07K Cr | 4.38K Cr | 2.61K Cr | 3.37K Cr | — |
| Other Non Operating Income Expenses | 621.85 Cr | 518.60 Cr | 128.84 Cr | 134.56 Cr | — |
| Special Income Charges | 0.00 | -191.86 Cr | -10.73 Cr | -116.21 Cr | — |
| Other Special Charges | 191.86 Cr | -154.09 Cr | -13.23 Cr | -76.01 Cr | — |
| Net Non Operating Interest Income Expense | -457.24 Cr | -289.71 Cr | 5.41 Cr | -17.04 Cr | — |
| Interest Expense Non Operating | 457.24 Cr | 289.71 Cr | 128.95 Cr | 36.84 Cr | — |
| Operating Income | 4.96K Cr | 4.32K Cr | 2.54K Cr | 3.30K Cr | — |
| Operating Expense | 13.40K Cr | 11.78K Cr | 10.18K Cr | 9.25K Cr | — |
| Other Operating Expenses | 7.62K Cr | 6.63K Cr | 3.13K Cr | 2.39K Cr | — |
| Depreciation And Amortization In Income Statement | 1.65K Cr | 1.52K Cr | 1.24K Cr | 1.13K Cr | — |
| Depreciation Income Statement | 1.65K Cr | 1.52K Cr | 833.29 Cr | 797.86 Cr | — |
| Gross Profit | 18.35K Cr | 16.10K Cr | 12.72K Cr | 12.55K Cr | — |
| Cost Of Revenue | 13.03K Cr | 12.60K Cr | 11.90K Cr | 10.82K Cr | — |
| Total Revenue | 31.38K Cr | 28.70K Cr | 24.62K Cr | 23.37K Cr | — |
| Operating Revenue | 31.38K Cr | 28.70K Cr | 24.62K Cr | 23.37K Cr | — |
| Interest Income | — | 285.76 Cr | 145.89 Cr | 31.60 Cr | 22.37 Cr |
| Rent Expense Supplemental | — | 120.42 Cr | 133.76 Cr | 124.19 Cr | 122.54 Cr |
| Write Off | — | 229.81 Cr | 0.00 | -2.23 Cr | 28.16 Cr |
| Impairment Of Capital Assets | — | 62.37 Cr | 23.96 Cr | 192.22 Cr | 0.00 |
| Restructuring And Mergern Acquisition | — | 98.66 Cr | 0.00 | — | -152.85 Cr |
| Total Other Finance Cost | — | 21.62 Cr | 11.53 Cr | 11.80 Cr | 14.92 Cr |
| Interest Income Non Operating | — | 285.76 Cr | 145.89 Cr | 31.60 Cr | 22.37 Cr |
| Amortization | — | 573.77 Cr | 411.29 Cr | 328.66 Cr | 253.78 Cr |
| Research And Development | — | 75.63 Cr | 39.51 Cr | 65.24 Cr | 68.81 Cr |
| Selling General And Administration | — | 2.50K Cr | 2.35K Cr | 2.18K Cr | 2.43K Cr |
| Selling And Marketing Expense | — | 1.68K Cr | 1.69K Cr | 1.50K Cr | 1.56K Cr |
| General And Administrative Expense | — | 817.69 Cr | 662.41 Cr | 680.35 Cr | 865.55 Cr |
| Rent And Landing Fees | — | 120.42 Cr | 133.76 Cr | 124.19 Cr | 122.54 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Aurobindo Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.